Wilms Tumor (Nephroblastoma)-Pipeline Review, H2 2016

Wilms Tumor (Nephroblastoma)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8891IDB
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Wilms' Tumor (Nephroblastoma)-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilms' Tumor (Nephroblastoma)-Pipeline Review, H2 2016, provides an overview of the Wilms' Tumor (Nephroblastoma) (Oncology) pipeline landscape.

Wilms' tumor or nephroblastoma is cancer of the kidneys that typically occurs in children, rarely in adults. Its common name is an eponym.Wilms' tumor is a rare kidney cancer that primarily affects children.Wilms' tumor most often occurs in just one kidney, though it can sometimes be found in both kidneys at the same time. Typical symptoms are: an abnormally large abdomen, abdominal pain, fever, nausea and vomiting, blood in the urine (in about 20% of cases) and high blood pressure in some cases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wilms' Tumor (Nephroblastoma)-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Wilms' Tumor (Nephroblastoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Wilms' Tumor (Nephroblastoma) (Oncology).

The pipeline guide reviews pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Wilms' Tumor (Nephroblastoma) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Wilms' Tumor (Nephroblastoma) Overview 6

Therapeutics Development 7

Pipeline Products for Wilms' Tumor (Nephroblastoma)-Overview 7

Pipeline Products for Wilms' Tumor (Nephroblastoma)-Comparative Analysis 8

Wilms' Tumor (Nephroblastoma)-Therapeutics under Development by Companies 9

Wilms' Tumor (Nephroblastoma)-Therapeutics under Investigation by Universities/Institutes 10

Wilms' Tumor (Nephroblastoma)-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Wilms' Tumor (Nephroblastoma)-Products under Development by Companies 13

Wilms' Tumor (Nephroblastoma)-Products under Investigation by Universities/Institutes 14

Wilms' Tumor (Nephroblastoma)-Companies Involved in Therapeutics Development 15

Exelixis Inc 15

NanoSmart Pharmaceuticals Inc 16

Recombio SL 17

Selvita SA 18

Wilms' Tumor (Nephroblastoma)-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

cabozantinib s-malate-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Cellular Immunotherapy for Oncology-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibody Conjugate for Wilms' Tumor-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

racotumomab-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

SEL-12034-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Wilms' Tumor (Nephroblastoma)-Dormant Projects 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Figures

Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016 7

Number of Products under Development for Wilms' Tumor (Nephroblastoma)-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Top 10 Targets, H2 2016 20

Number of Products by Stage and Top 10 Targets, H2 2016 20

Number of Products by Top 10 Mechanism of Actions, H2 2016 22

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

List of Tables

Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016 7

Number of Products under Development for Wilms' Tumor (Nephroblastoma)-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Wilms' Tumor (Nephroblastoma)-Pipeline by Exelixis Inc, H2 2016 15

Wilms' Tumor (Nephroblastoma)-Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 16

Wilms' Tumor (Nephroblastoma)-Pipeline by Recombio SL, H2 2016 17

Wilms' Tumor (Nephroblastoma)-Pipeline by Selvita SA, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Wilms' Tumor (Nephroblastoma)-Dormant Projects, H2 2016 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Exelixis Inc, NanoSmart Pharmaceuticals Inc, Recombio SL, Selvita SA

Wilms Tumor (Nephroblastoma) Therapeutic Products under Development, Key Players in Wilms Tumor (Nephroblastoma) Therapeutics, Wilms Tumor (Nephroblastoma) Pipeline Overview, Wilms Tumor (Nephroblastoma) Pipeline, Wilms Tumor (Nephroblastoma) Pipeline Assessment

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com